Clinical Relevance of Anti-HLA Donor-Specific Antibodies Detected by Luminex Assay in the Development of Rejection After Renal Transplantation


    loading  Checking for direct PDF access through Ovid

Abstract

BackgroundThe role of anti–human leukocyte antigen (HLA) donor-specific antibodies (DSA) detected by Luminex in the development of rejection is not fully understood.MethodsA study including 369 patients who received transplants from deceased donors with a negative complement-dependent cytotoxicity crossmatch (XM) was performed. From the total of patients, 151 underwent a renal biopsy because of renal dysfunction, whereas the 218 remaining showed a stable renal function, and no rejection was assumed. Diagnosis and type of rejection was based in biopsy data.ResultsPatients with a positive virtual XMs showed more rejection episodes of any types when comparing with patients with negative virtual XMs (P<0.0001). Nevertheless, there were no significant differences between patients without anti-HLA antibodies and patients with anti-HLA no DSA. Allograft impairment was caused by a rejection episode in 84% (32/38) of patients with anti–HLA-DSA but only in 30% (34/113) of patients without anti–HLA-DSA. Regarding the type of rejection detected in the biopsy, all the patients with de novo (after transplantation) anti–HLA-DSA were diagnosed as antibody-mediated rejection (AMR) or AMR+T-cell–mediated rejection, whereas most of the patients without anti–HLA-DSA (68%) were diagnosed with T-cell–mediated rejection, and patients with preexistent anti–HLA-DSA showed a more homogeneous distribution of the different types of rejection.ConclusionsAccording to our results, patients with preformed or de novo anti–HLA-DSA showed the highest likelihood to suffer rejection episodes. Transplantation with preformed anti–HLA-DSA should be avoided, and an early detection of de novo HLA antibodies is important to treat patients before damage occurs in the graft.

    loading  Loading Related Articles